Tetanus

Tetanus is an infection due to spore-forming *Clostridium tetani* bacteria, with disease expression driven by release of tetanus neurotoxin ^[1][2]. The organism is described in the sources as the cause of tetanus, while the toxin is noted as among the most potent known ^[2]. The provided material does not supply a more detailed formal case definition, incubation period, or microbiologic diagnostic criteria ^[1][2].

The sources describe tetanus as producing muscle spasms, rigidity, and dysautonomia ^[1]. Important complications include laryngeal spasm with possible airway obstruction and respiratory arrest, as well as nosocomial infections and sequelae of prolonged immobility ^[1]. The condition is characterized as a diagnosis not to miss, and with prolonged, quality intensive care, many patients may survive with good functional outcome ^[1]. Source-backed detail on symptom timing, common prodromal features, or neurologic exam findings is not yet available ^[1].

Tetanus is currently described as a rarity in high-income countries ^[1]. Deaths from tetanus fell by almost 90% between 1990 and 2019, which the source attributes largely to the success of WHO’s Maternal and Neonatal Tetanus Elimination campaign ^[1]. Despite this decline, deaths among children and adults have plateaued, and tetanus remains an important vaccine-preventable cause of morbidity and mortality, notably in southern Asia, southeast Asia, and sub-Saharan Africa ^[1]. The provided material does not give incidence figures, age-specific attack rates, or outbreak summaries beyond this global distribution ^[1].

Tetanus is usually acquired through contaminated wounds and burns ^[1]. The source material indicates that infection follows exposure of susceptible tissue to spores of *C. tetani* rather than person-to-person spread, and it also notes retrograde transport of tetanus neurotoxin within motor neurons ^[1][2]. Additional exposure details, environmental persistence parameters, and any host-to-host transmission information are not provided in the snippets ^[1][2].

The provided sources do not enumerate detailed host risk groups, so source-backed detail on specific occupational, age, or immunization-status subgroups is not yet available ^[1][3]. The text does indicate that deaths among children and adults have plateaued, and that the disease remains important in southern Asia, southeast Asia, and sub-Saharan Africa, which may be useful for contextual risk interpretation ^[1].

The available sources support tetanus as a vaccine-preventable disease and note that the decline in deaths has reflected the WHO Maternal and Neonatal Tetanus Elimination campaign ^[1]. One source also includes a general safety review of routine vaccines used in the United States, but it does not provide tetanus-specific schedules or product details in the snippet ^[3]. Source-backed detail on wound prophylaxis protocols, booster timing, or other specific preventive measures is not yet available ^[1][3].

In monitoring contexts, tetanus should be interpreted as an uncommon but still serious vaccine-preventable disease, with continuing burden concentrated outside high-income settings ^[1]. The source emphasizes that clinical recognition is central, because tetanus is usually diagnosed on the basis of signs and symptoms, while microbiological tests serve as adjuncts ^[1]. Surveillance summaries should therefore be read with attention to geographic context, severe neurologic manifestations, and the possibility of under-recognition in resource-constrained settings ^[1].

1. 1 Sudarshan R et al. Tetanus: recognition and management. Lancet Infect Dis. 2025 Nov. PMID: 40543524. doi: 10.1016/S1473-3099(25)00292-0. PubMed: https://pubmed.ncbi.nlm.nih.gov/40543524/
2. 2 Dong M et al. Botulinum and Tetanus Neurotoxins. Annu Rev Biochem. 2019 Jun 20. PMID: 30388027. doi: 10.1146/annurev-biochem-013118-111654. PubMed: https://pubmed.ncbi.nlm.nih.gov/30388027/
3. 3 Gidengil C et al. Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis. Vaccine. 2021 Jun 23. PMID: 34049735. doi: 10.1016/j.vaccine.2021.03.079. PubMed: https://pubmed.ncbi.nlm.nih.gov/34049735/
4. 4 Tetanus-Adsorbatimpfstoff - Tetanus-Antitoxin. 2. AB – DDR. Rezepturen R – Z. 1977. doi: 10.1515/9783112658987-050. DOI: https://doi.org/10.1515/9783112658987-050
5. 5 Tetanus, nieuwe richtlijnentetanus tetanus, richtlijnen tetanus, vaccinatie tetanus, booster tetanus, TIG. Bijblijven. 2003. doi: 10.1007/bf03059743. DOI: https://doi.org/10.1007/bf03059743
6. 6 Tetanus. Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie. 2015. doi: 10.1007/s40664-014-0079-4. DOI: https://doi.org/10.1007/s40664-014-0079-4

ICD-10

ICD-11

Total cases

12K

Peak month

2011-09

Coverage

7 reporting countries · 2000-01-01 → 2026-06-20